3-(4-morpholino-3-nitrobenzoyl)butyric acid | 103585-32-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(4-morpholino-3-nitrobenzoyl)butyric acid
• 英文别名: 4(4-morpholino-3-nitrophenyl)-4-oxo-3-methylbutanoic acid；3-methyl-4-(4-morpholin-4-yl-3-nitrophenyl)-4-oxobutanoic acid
• CAS: 103585-32-6
• 化学式: C₁₅H₁₈N₂O₆
• 分子量: 322.318
• InChiKey: CCFWPUWAAICLOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-(4-morpholino-3-nitrobenzoyl)butyric acid 在 palladium on activated charcoal 氢气 、 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、303.98 kPa 条件下， 反应 4.0h， 生成 6-(3-amino-4-morpholinophenyl)-5-methyl-4,5-dihydro-2H-pyridazine-3-one
  参考文献：
  名称：

  6-(4-Morpholino-phenyl)-4,5-dihydro-2H-pyridazine-3-ones: potent platelet aggregation inhibitors and antithrombotics

  摘要：

  A series of di- and tri-substituted 6-phenyl-4,5-dihydro-2H-pyridazine-3-ones is described. The compounds were designed to be antithrombotics and were assessed for their inhibitory properties on platelet aggregation and on thrombus formation in an arteriovenous shunt in the rat. The synthesis and physical properties of the compounds are described. The structure-activity relationships reveal that non-aromatic nitrogen-containing heterocycles can confer high activity on the 6-phenyl-pyridazinone system, provided they are combined with an additional electron-withdrawing substituent in the phenyl ring. The most potent compounds (8i, 8b) had an ED(min) of 1-3 mg/kg after oral administration in the thrombus formation test.

  DOI：

  10.1016/0223-5234(91)90121-3
• 作为产物：
  描述：

  α-morpholino-α-(4-morpholino-3-nitro-phenyl)-acetonitrile 在 盐酸 、 氢氧化钾 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 24.67h， 生成 3-(4-morpholino-3-nitrobenzoyl)butyric acid
  参考文献：
  名称：

  6-(4-Morpholino-phenyl)-4,5-dihydro-2H-pyridazine-3-ones: potent platelet aggregation inhibitors and antithrombotics

  摘要：

  A series of di- and tri-substituted 6-phenyl-4,5-dihydro-2H-pyridazine-3-ones is described. The compounds were designed to be antithrombotics and were assessed for their inhibitory properties on platelet aggregation and on thrombus formation in an arteriovenous shunt in the rat. The synthesis and physical properties of the compounds are described. The structure-activity relationships reveal that non-aromatic nitrogen-containing heterocycles can confer high activity on the 6-phenyl-pyridazinone system, provided they are combined with an additional electron-withdrawing substituent in the phenyl ring. The most potent compounds (8i, 8b) had an ED(min) of 1-3 mg/kg after oral administration in the thrombus formation test.

  DOI：

  10.1016/0223-5234(91)90121-3

文献信息

• Alkyl substituted pyridazinones and pharmaceutical compositions
  申请人：Ciba-Geigy Corporation

  公开号：US04629789A1

  公开（公告）日：1986-12-16

  The present invention relates to novel 6-phenyl-5-alkyl substituted-4,5-dihydro-3(2H)-pyridazinones of formula I: ##STR1## in which R.sub.1 is halogen, lower alkyl, lower alkoxy, NO.sub.2, NH.sub.2, NHCOR.sub.3 (R.sub.3 is H or C.sub.1 -C.sub.4 alkyl), CN, carboxy, lower alkoxycarbonyl, carbamoyl, CF.sub.3, or OH and R.sub.2 is C.sub.1 -C.sub.4 alkyl; the tautomeric forms and salts thereof; as their racemic mixtures or as the individual optically-active forms. Compounds (I) are useful in pharmaceutical preparations having improved antithrombotic activity.

  本发明涉及新型的6-苯基-5-烷基取代-4,5-二氢-3(2H)-吡啶酮，化学式为I：##STR1## 其中R.sub.1是卤素、较低烷基、较低烷氧基、NO.sub.2、NH.sub.2、NHCOR.sub.3（R.sub.3为H或C.sub.1 -C.sub.4烷基）、CN、羧基、较低烷氧羰基、氨基甲酰基、CF.sub.3或OH，R.sub.2是C.sub.1 -C.sub.4烷基；它们的互变异构体和盐；作为它们的外消旋混合物或作为单体光学活性形式。化合物(I)在具有改良抗血栓活性的药物制剂中有用。
• Alkyl substituted pyridazinones, processes for producing them, pharmaceutical preparations containing these compounds, and the use thereof
  申请人：CIBA-GEIGY AG

  公开号：EP0180542A2

  公开（公告）日：1986-05-07

  The present invention relates to novel 6-phenyl-5-alkyl substituted-4,5-dihydro-3-(2H)-pyridazinones of formula I: in which R, is halogen, lower alkyl, lower alkoxy, No2, NH2, NHCOR3 (R, is H or C1-C4 alkyl), CN, carboxy, lower alkoxycarbonyl, carbamoyl, CF3, or OH and R2 is C1-C4 alkyl; the tautomeric forms and salts thereof; as their racemic mixtures or as the individual optically-active forms. Compounds (I) are useful in pharmaceutical preparations having improved antithrombotic activity.

  本发明涉及式 I 的新型 6-苯基-5-烷基取代-4,5-二氢-3-(2H)-哒嗪酮：其中 R，是卤素、低级烷基、低级烷氧基、No2、NH2、NHCOR3（R，是 H 或 C1-C4烷基）、CN、羧基、低级烷氧基羰基、氨基甲酰基、CF3 或 OH，R2 是 C1-C4 烷基；其同分异构体及其盐；作为它们的外消旋混合物或作为单独的光学活性形式。 化合物 (I) 可用于提高抗血栓活性的药物制剂中。
• US4629789A
  申请人：——

  公开号：US4629789A

  公开（公告）日：1986-12-16
• US4699908A
  申请人：——

  公开号：US4699908A

  公开（公告）日：1987-10-13
• 6-(4-Morpholino-phenyl)-4,5-dihydro-2H-pyridazine-3-ones: potent platelet aggregation inhibitors and antithrombotics
  作者：R Goeschke、J Gainer、GA Howarth、RB Wallis、R Kerry、J Ambler、VS Findlay、KD Butler

  DOI：10.1016/0223-5234(91)90121-3

  日期：1991.10

  A series of di- and tri-substituted 6-phenyl-4,5-dihydro-2H-pyridazine-3-ones is described. The compounds were designed to be antithrombotics and were assessed for their inhibitory properties on platelet aggregation and on thrombus formation in an arteriovenous shunt in the rat. The synthesis and physical properties of the compounds are described. The structure-activity relationships reveal that non-aromatic nitrogen-containing heterocycles can confer high activity on the 6-phenyl-pyridazinone system, provided they are combined with an additional electron-withdrawing substituent in the phenyl ring. The most potent compounds (8i, 8b) had an ED(min) of 1-3 mg/kg after oral administration in the thrombus formation test.